Natera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy Sells 705 Shares

Natera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy sold 705 shares of the stock in a transaction on Thursday, April 25th. The shares were sold at an average price of $89.55, for a total value of $63,132.75. Following the transaction, the chief financial officer now directly owns 71,397 shares of the company’s stock, valued at $6,393,601.35. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Michael Burkes Brophy also recently made the following trade(s):

• On Tuesday, April 23rd, Michael Burkes Brophy sold 1,523 shares of Natera stock. The stock was sold at an average price of $91.38, for a total value of $139,171.74.
• On Tuesday, April 2nd, Michael Burkes Brophy sold 1,378 shares of Natera stock. The shares were sold at an average price of $92.62, for a total transaction of $127,630.36.
• On Thursday, March 28th, Michael Burkes Brophy sold 914 shares of Natera stock. The shares were sold at an average price of $90.42, for a total value of $82,643.88.
• On Tuesday, March 5th, Michael Burkes Brophy sold 2,826 shares of Natera stock. The stock was sold at an average price of $88.36, for a total transaction of $249,705.36.
• On Tuesday, February 6th, Michael Burkes Brophy sold 34,029 shares of Natera stock. The shares were sold at an average price of $70.03, for a total value of $2,383,050.87.
• On Thursday, February 1st, Michael Burkes Brophy sold 22,281 shares of Natera stock. The stock was sold at an average price of $67.73, for a total value of $1,509,092.13.
• On Monday, January 29th, Michael Burkes Brophy sold 3,235 shares of Natera stock. The shares were sold at an average price of $65.09, for a total value of $210,566.15.

Natera Stock Up 0.4 %

NASDAQ NTRA opened at $91.66 on Friday. Natera, Inc. has a 1-year low of $36.90 and a 1-year high of $98.82. The stock’s 50 day moving average is $87.72 and its two-hundred day moving average is $67.16. The company has a quick ratio of 3.96, a current ratio of 4.10 and a debt-to-equity ratio of 0.37.

Natera (NASDAQ:NTRA) last announced its quarterly earnings results on Wednesday, February 28th. The medical research company reported ($0.64) EPS for the quarter, beating the consensus estimate of ($0.73) by $0.09. Natera had a negative return on equity of 62.19% and a negative net margin of 40.16%. The business had revenue of $311.11 million for the quarter, compared to analyst estimates of $300.38 million. As a group, equities analysts expect that Natera, Inc. will post -2.35 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the stock. The Goldman Sachs Group raised their target price on shares of Natera from $90.00 to $100.00 and gave the company a “buy” rating in a research note on Monday, April 15th. Craig Hallum started coverage on Natera in a research note on Monday, April 8th. They set a “buy” rating and a $117.00 target price for the company. StockNews.com downgraded Natera from a “hold” rating to a “sell” rating in a research report on Tuesday. BTIG Research increased their price objective on Natera from $75.00 to $85.00 and gave the company a “buy” rating in a research report on Friday, December 29th. Finally, Raymond James downgraded shares of Natera from a “strong-buy” rating to an “outperform” rating and raised their price objective for the stock from $68.00 to $85.00 in a research note on Tuesday, February 20th. One analyst has rated the stock with a sell rating and fourteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $86.40.

Institutional Investors Weigh In On Natera

A number of hedge funds have recently made changes to their positions in the company. Norges Bank bought a new stake in Natera during the fourth quarter worth about $83,970,000. American Century Companies Inc. grew its position in Natera by 115.7% during the 3rd quarter. American Century Companies Inc. now owns 1,654,303 shares of the medical research company’s stock worth $73,203,000 after acquiring an additional 887,409 shares during the last quarter. Invesco Ltd. increased its holdings in Natera by 52.0% during the 3rd quarter. Invesco Ltd. now owns 2,529,496 shares of the medical research company’s stock valued at $111,930,000 after purchasing an additional 865,404 shares in the last quarter. Perceptive Advisors LLC increased its holdings in Natera by 289.7% during the 4th quarter. Perceptive Advisors LLC now owns 850,225 shares of the medical research company’s stock valued at $53,258,000 after purchasing an additional 632,047 shares in the last quarter. Finally, Vanguard Group Inc. raised its position in Natera by 5.7% in the 4th quarter. Vanguard Group Inc. now owns 10,971,895 shares of the medical research company’s stock valued at $687,280,000 after purchasing an additional 588,147 shares during the last quarter. Institutional investors and hedge funds own 99.90% of the company’s stock.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.